Project Grant F30CA298183

Award Date 8/14/25
Completion Date 3/31/29
Dollars Obligated $83K
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $607,250 to the Scripps Research Institute in La Jolla, CA to investigate the role of DNA polymerase theta (POLQ) in repairing replication-associated DNA double-strand breaks and exploiting this as a potential cancer treatment strategy. The award period runs from September 1, 2024 to August 31, 2029. The key objectives of this research project are to...
The National Cancer Institute awarded a $218,068 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Scripps Research Institute in California. The purpose of this 18-month award, effective September 26, 2024, is to elucidate the molecular mechanism of microhomology-mediated end joining (MMEJ) by DNA polymerase theta (POLTh), a key player in this error-prone DNA double-strand break repair pathway. The research aims to define the relationship between POLTh and MMEJ DNA...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $238,722 to the Sloan-Kettering Institute for Cancer Research to investigate the role of mutagenic DNA repair in the persistence of cancer cells. The key objectives are to: Investigate persistence in response to PARP inhibitor treatment of BRCA1/2 cancer cells Examine mechanisms of mutagenic DNA repair in persister colorectal cancer cells Use high-content microscopy to...
This Project Grant award of $487,393.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports research on backup DNA repair mechanisms in homologous recombination deficient (HRD) cancers. The research aims to determine the role of key proteins like RAD52, HELQ, and POLQ in backup double-strand break repair pathways when the primary homologous recombination pathway is inactivated in certain cancer types. The goal is to identify...
This Project Grant award, identified as R01GM152613, was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training (CFDA 93.859) federal grant program. The award, totaling $680,400.00, will fund research at The University of Texas M.D. Anderson Cancer Center in Houston, TX to investigate the link between replication fork protection and the innate immune response. The key objectives of this 4-year project are to: 1) delineate how...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), is funding research at the Sloan-Kettering Institute for Cancer Research to investigate the molecular mechanisms of eukaryotic chromosome replication. The $1,350,554.00 award will support a 5-year research project that aims to elucidate the intrinsic mechanisms of the eukaryotic DNA replication machinery and its response to various...
This $390,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training (CFDA 93.859) program supports research to elucidate the mechanisms underlying DNA double-strand break repair at Thomas Jefferson University's Sidney Kimmel Medical College. The project aims to use cutting-edge microscopy and biochemical techniques to map the dynamics of DNA repair proteins and better understand how the multi-enzyme complex...
This federal Project Grant award of $404,792 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports research to investigate the mechanisms regulating telomere length, protection, and replication. The key objectives of this 5-year project are to: 1) determine how the POT1 protein coordinates telomere length maintenance through a phospho-dephospho switch, 2) explore how the TRF2-RAP1 complex protects...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $581,381 to the Sloan-Kettering Institute for Cancer Research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance. The research aims to better understand DNA damage repair pathways and how they contribute to genomic instability and cancer development, with the goal of informing more...
The National Institute of General Medical Sciences (NIGMS) awarded a $445,000 Project Grant under the Biomedical Research and Research Training (CFDA 93.859) federal grant program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant supports research to elucidate the molecular mechanisms of DNA double-strand break repair by homologous recombination, a high-fidelity DNA repair pathway that is critical for suppressing cancer development. Over the 5-year project...

DETERMINING THE ROLE OF REPLICATION PROTEIN A IN POLYMERASE THETA-MEDIATED END-JOINING - PROJECT SUMMARY MANY FRONTLINE CANCER TREATMENTS, INCLUDING RADIATION THERAPY AND SEVERAL CHEMOTHERAPEUTICS, WORK BY INDUCING DOUBLE-STRAND BREAKS (DSBS) SINCE CANCER CELLS ARE TYPICALLY MORE VULNERABLE TO DSBS THAN HEALTHY CELLS. THUS, UNDERSTANDING THE COMPLEX PATHWAYS CANCER CELLS USE TO REPAIR DSBS IS CRITICAL TO UNDERSTANDING AND ADDRESSING RESISTANCE TO THESE THERAPEUTIC AGENTS, WHICH ALMOST INVARIABLY ARISES. DEFICIENCIES IN THE HIGH FIDELITY DSB REPAIR PATHWAY HOMOLOGOUS RECOMBINATION PROMOTE TUMORIGENESIS. THE RESULTING CANCERS ARE DEPENDENT ON A MUTAGENIC DSB REPAIR PATHWAY CALLED POLYMERASE THETA-MEDIATED END-JOINING (TMEJ). POLYMERASE THETA (POLTh) IS A MULTIFUNCTIONAL ENZYME CONSISTING OF AN N-TERMINAL HELICASE DOMAIN, DISORDERED LINKER DOMAIN AND C-TERMINAL POLYMERASE DOMAIN. POLTh IS ESSENTIAL FOR TMEJ, BUT THE OTHER FACTORS INVOLVED IN THIS PATHWAY REMAIN POORLY DEFINED. WHILE GENETIC SCREENS HAVE REVEALED SEVERAL NON-ESSENTIAL PROTEINS THAT MAY PLAY A ROLE IN TMEJ, THESE SCREENS ARE INCAPABLE OF IDENTIFYING ESSENTIAL FACTORS THAT INTERACT WITH POLTh TO PROMOTE TMEJ. IN THIS PROPOSAL, I WILL DETERMINE THE ROLE OF THE ESSENTIAL, EUKARYOTIC SINGLE STRAND DNA-BINDING PROTEIN, REPLICATION PROTEIN A (RPA), IN TMEJ. BASED ON PARTIAL KNOCKDOWN IN CELLS, RPA WAS INITIALLY THOUGHT TO INHIBIT TMEJ.1 HOWEVER, WHEN I DEPLETED RPA FROM A CELL-FREE TMEJ ASSAY IN XENOPUS EGG EXTRACTS, END- JOINING WAS ABOLISHED. TMEJ WAS RESCUED WITH RECOMBINANT RPA, DEMONSTRATING THAT RPA IS ESSENTIAL FOR TMEJ. THE DEEP LEARNING TOOL ALPHA-FOLD MULTIMER PREDICTS THAT RPA AND POLTh INTERACT VIA TWO INTERFACES - ONE ON RPA1 AND ONE ON RPA2. WHEN I MUTATED THESE INTERFACES ON RPA, REPLICATION WAS UNAFFECTED BUT TMEJ WAS INHIBITED. MUTATING THE CORRESPONDING RESIDUES ON POLTh ALSO ABOLISHED TMEJ. I HYPOTHESIZE THAT THESE INTERFACES ARE NECESSARY FOR POLTh RECRUITMENT AND ANNEALING OF MICROHOMOLOGOUS REGIONS. IN AIM 1, I WILL TEST THE HYPOTHESIS THAT RPA1 BINDS AND RECRUITS POLTh AND THAT THIS ALLOWS POLTh TO BRIDGE TWO NON-HOMOLOGOUS STRANDS. IN AIM 2, I WILL TEST THE HYPOTHESIS THAT RPA2 PROMOTES TMEJ BY STIMULATING THE HELICASE DOMAIN OF POLTh TO SIMULTANEOUSLY BIND DNA, ANNEAL TWO DISTINCT STRANDS AND DESTABILIZE AND REMOVE RPA. UNDERSTANDING THE ROLE OF RPA IN TMEJ WILL PROVIDE FUNDAMENTAL INSIGHT INTO HOW POLTh INTERACTS WITH OTHER PROTEINS TO REPAIR DSBS BOTH IN HEALTH AND DISEASE.

Posted 2/14/25, 12:00 AM